DEPARTMENT OF DEFENSE REPORT SHOWS BACH PHARMA DRUG GVT REVERSES BRAIN DYSFUNCTION

GVT Repairs Hippocampal Dysfunction by Stem Cell Regeneration

NORTH ANDOVER, Massachusetts: August 1, 2017 – Bach Pharma, Inc. (BACH), a global leader in the discovery and commercialization of revolutionary therapeutics to treat life threatening diseases, announced that recent studies show GVT® reverses astrocyte hypertrophy and supports generation of new stem cells and neurons in the hippocampus, indicating that the drug could be an effective treatment for victims of Gulf War Illness (GWI).
GWI is a chronic, multi-symptom illness affecting approximately 250,000 of the nearly 700,000 U.S. servicemen and women who served in the Gulf War from August 1990 through February 1991. Veterans of allied forces, including those from the US, United Kingdom and Australia, continue to suffer from GWI symptoms including brain dysfunction, memory impairment, depression, and anxiety.

The study, conducted by Ashok K. Shetty, PhD, Associate Director and Professor at the Institute for Regenerative Medicine at the College of Medicine at Texas A&M University System, confirmed that exposure to chemicals and stress caused astrocytic hypertrophy and neuronal stem cell inactivity in the hippocampus of the brain. Ashok K. Shetty, PhD, is a world-renowned expert in modeling Gulf War Illness. The study, prepared under a grant from the Department of Defense (DOD) for the U.S. Army Medical Research and Material Command, Fort Detrick, Maryland, demonstrated that treatment with BACH’s lead drug compound, GVT, normalized the production of neurons in the hippocampus by stem cell proliferation.

According to the results of Dr. Shetty’s report, GVT reverses astrocyte hypertrophy, a condition that makes the astrocyte incapable of protecting neurons. Astrocyte hypertrophy is a contributing factor in the progression of Gulf War Illness. Specifically, GVT was found to regenerate stem cells and neurons. GVT treatment improved cognitive function and reversed mood impairment, particularly anhedonia, while modulating oxidative stress in the hippocampus of GWI animals.

GVT treatment was shown to reverse recognition and location memory dysfunction and improve cognitive ability while normalizing oxidative stress in the hippocampus and cerebral cortex. In addition to normalizing astrocytic hypertrophy, GVT treatment also normalized neuronal stem cell activity in the hippocampus, and reduced the numbers of activated microglia/macrophages in the hippocampus.

The chemicals troops were exposed to in the Persian Gulf included pyridostigmine bromide, which was used as prophylaxis to prevent death in an attack with nerve gas agents. In addition, mosquito repellants, such as DEET, and pesticides, such as permethrin, were sprayed on their clothes and tents to keep potentially disease-carrying insects and rodents at bay. Some troops were also likely exposed to low levels of chemical warfare agents, due to demolition of Iraqi facilities storing those agents, and smoke from oil well fires.

Chemicals such as DEET and permethrin can enter the brain through disruption of the blood-brain barrier, where they can inhibit the breakdown of a neurotransmitter called acetylcholine. “Essentially, they cause acetylcholine to build up in the brain, causing hyperexcitability of neurons as well as the death of some neurons, which leads to inflammation in the brain,” said Ashok K. Shetty, PhD.

“Our data in animal models matches very well with what has been seen in patients,” Shetty said. They both had considerable systemic inflammation, which can be measured by levels of multiple pro-inflammatory cytokines in the blood serum. Pro-inflammatory cytokines circulate all over the body and cause systemic inflammation, which, in turn, can cause considerable problems in certain vulnerable regions of the brain such as the hippocampus. These problems include declined production of new neurons important for making new memories.

“GVT is not only neuro-protective, but also neuro-generative,” according to Mark O. Henry, CFO of BACH. “We have now shown in two different animal models that GVT can regenerate neurons. The fact that GVT regenerates stem cells and neurons was an unexpected finding.” Based on the results announced today, Dr. Shetty has established a collaboration with Dena Davidson, PhD, deputy director of research at the Veterans Integrated Service Network (VISN) 17 Center of Excellence for Research on Returning War Veterans in Waco, Texas, to pursue clinical trials in GWI patients.
“Poisoning of the brain due to chemicals widely used in modern industrial societies is a widespread issue around the world. We believe GVT has potential as a therapeutic treatment for disorders associated with a wide range of chemical poisoning,” noted BACH’s Chairman of the Board, Dr. Steven L. Stroup, MD, who also stated: “In the U.S. alone, it is believed that 30 percent of the U.S. population suffers some form of brain poisoning related to chemicals and stress.”

About Bach Pharma, Inc.: Bach Pharma, Inc. (BACH), a privately held research and development pharmaceutical company, directs the development of therapies for degenerative neurological illnesses. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties, which research has shown can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. Due to its strong safety profile along with its ability to cross the retinal and the blood-brain barriers and enter cells of the central nervous system, GVT has the potential to treat serious diseases of the central nervous and immune systems and dramatically reduce the cost of global health care.

BACH is a proud member of the Massachusetts Biotechnology Council and a host company for the Massachusetts Life Science Center Internship Challenge.

For more information, contact Mark O. Henry, CFO, 978-794-5510, mhenry@bachpharma.com.
###

BACH PHARMA ANNOUNCES APPOINTMENT OF DR. PRAVIN CHATURVEDI TO BOARD OF DIRECTORS

North Andover, MA, USA August 3, 2016 – Bach Pharma Inc., a Delaware Corporation, announced the appointment of Dr. Pravin Chaturvedi to the Board of Directors. Dr. Chaturvedi has deep experience in building biotechnology companies both as a scientist and entrepreneur. He is the President and Chief Executive Officer of Boston and Vancouver-based Pivot Pharmaceuticals, Inc., which recently acquired Boston-based IndUS Pharmaceuticals, a company concerned with the discovery and development of small molecule drugs for the treatment of cancer, diabetes and infectious diseases. IndUS was founded and led by Dr. Chaturvedi until its acquisition. Additionally, Dr. Chaturvedi is the co-founder of Florida-based Oceanyx Pharmaceuticals. He remains an advisor to San Francisco-based Napo Pharmaceuticals, where he was the President and Chief Scientific Officer. Prior to his tenures at Pivot, IndUS, and Napo, he was the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals, which was acquired by Wyeth (now Pfizer). He has also served as Head of Lead Evaluation at Vertex Pharmaceuticals. Dr. Chaturvedi will support Bach’s initiatives as a key scientific advisor in addition to being a non-executive board member.

“I believe Bach has the potential for the development of treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) which represents a very high unmet medical need and could benefit from the development of Bach’s lead candidate GVT” stated Dr. Chaturvedi about his appointment to the Board of Directors. “Dr. Chaturvedi brings extensive scientific expertise to our board and his contributions will be a key element of Bach’s future success” states Bach Pharma CEO Kelly Blackburn.

“His knowledge and experience in building successful companies will be invaluable as we move forward with the development of GVT.”

ABOUT BACH PHARMA

Bach Pharma, Inc., (BACH), a privately held pharmaceutical company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life threatening diseases. BACH is targeting the development of therapies for life threatening oxidative stress-related diseases with the goal to dramatically improve patients’ lives and reduce the cost of global health care. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties and scavenges free radicals. Research has shown that GVT can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. GVT has the potential to treat various serious diseases of the central nervous and immune systems. Bach has intellectual property for GVT as well as multiple derivatives. The leading program will be focused on severe rare neurological diseases. Bach is a proud member of the MassBio Council and a host company for the Massachusetts Life Science Center Internship Challenge. Media Contact: Mark Henry, CFO Telephone: 978-794-5510 Email: mhenry@bachpharma.com

BACH PHARMA APPOINTS KELLY BLACKBURN AS CHIEF EXECUTIVE OFFICER

NORTH ANDOVER, MASSACHUSETTS, USA, July 5, 2016 – Bach Pharma Inc., a Delaware Corporation, today announced the appointment of Kelly Blackburn as Chief Executive Officer and as a member of the Bach Pharma Board of Directors. Ms. Blackburn will lead the company into their next stage of development, bringing the company’s lead candidate, GVT®, into the clinic.

“I am excited for the opportunity to advance this company to the next stage” said Kelly Blackburn, CEO, Bach Pharma. “I believe there is great potential to improve patients’ lives with these therapeutics. With their lead candidate, GVT, Bach Pharma is on the cutting edge of development for the treatment of life threatening neurological diseases.”

Bach Pharma also announced that Mark O. Henry will serve as Chief Financial Officer, transitioning from his role as CEO. Mr. Henry expressed his enthusiasm regarding the addition of Ms. Blackburn to the team, “Kelly is an accomplished executive in the healthcare industry who brings deep experience in running pharmaceutical operations to this role. We are thrilled to have her on board.”

Ms. Blackburn was previously Vice President of Clinical Affairs at aTyr Pharma in San Diego, California where as a member of the Executive Leadership Team, she was responsible for the oversight of clinical and regulatory plans for all programs. Ms. Blackburn has worked in several other pharmaceutical companies including Vertex pharmaceuticals where she led the operations for their portfolio. Her successes include approvals for transformative therapies in Cystic Fibrosis, Hepatitis C and Multiple Myeloma.

ABOUT BACH PHARMA

Bach Pharma, Inc., (BACH), a privately held pharmaceutical company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life threatening diseases. BACH is targeting the development of therapies for life threatening oxidative stress-related diseases with the goal to dramatically improve patients’ lives and reduce the cost of global health care.

The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties. Research has shown that GVT can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. GVT has the potential to treat various serious diseases of the central nervous and immune systems. Bach has intellectual property for GVT as well as multiple derivatives. The leading program will be focused on severe rare neurological diseases.

Bach is a proud member of the MassBio Council and a host company for the Massachusetts Life Science Center Internship Challenge.
###
Media Contact: Mark O. Henry, CFO
Email: mhenry@bachpharma.com
Telephone: 978-794-5510

POSSIBLE HOPE FOR VETERANS SUFFERING FROM GULF WAR ILLNESS

DOD AND BACH PHARMA RELEASE PHASE 1 REPORT DEMONSTRATING GVT® SHOWS CONSIDERABLE PROMISE FOR ALLEVIATING COGNITIVE IMPAIRMENT AND MOOD DISFUNCTION CAUSED BY GWI

North Andover, MA, January 30, 2016 – The Department of Defense (DOD) and Bach Pharma recently announced that data collected from studies conducted by the Veterans Administration suggest that oral administration of GVT® has considerable promise for alleviating cognitive impairment and mood dysfunction in GWI rats. Gulf War Illness (GWI) is a chronic multi-symptom health problem which afflicts nearly 30% of veterans who served in the Persian Gulf War. Brain dysfunction, typified by memory dysfunction, depression and anxiety, is one of the major health issues in GWI. The full report is available on the DOD’s public website.

Bach’s lead candidate GVT® is a novel cytoprotective agent. GVT® has powerful anti-oxidant and anti-inflammatory properties and scavenges free radicals. GVT® has the ability to cross the blood-brain barrier and enter cells of the central nervous system, as well as to enter the immune system, thereby delivering therapeutic results to the gut, thymus, spleen and blood. GVT® is also able to cross the retinal-brain barrier.

Phase 1 results from the multi-year study discovered that SOD-2 (the gene that encodes mitochondrial superoxide dismutase 2 protein) was one of twenty culprits involved in Gulf War Illness. “Administered at high doses, GVT® reversed all of the SOD-2 damage done to the mitochondria of the neurons. In addition, GVT® also showed very positive results regarding SOD-1,” stated Bach’s Principal Investigator Professor Paul K.Y. Wong, PhD, University of Texas MD Anderson Cancer Center, Smithville, Texas. The results suggest that mood impairment, particularly anhedonia (the inability to feel pleasure) as well as cognitive impairment pertaining to pattern separation, could be reversed with oral administration of moderate to high dose of GVT® in GWI rats. GVT® treatment modulates oxidative stress in the hippocampus of GWI rats. Furthermore, 20 genes that displayed increased expression in GWI rats were normalized to control levels with higher doses of GVT® treatment. In Phase 2 of this study the DOD will commence experiments involving the exposure of animals to Gulf War Illness-related (GWIR) chemicals and stress followed by GVT® treatment at extended time points after exposure.

When releasing the report the DOD announced “these are very interesting initial findings”.

George Hillman, Director of Business Development at Bach, stated “Bach is committed to working with the DOD and with the VA to improve the health care of all veterans and military personnel”.

This study was funded by the DOD, Bach Pharma, The Longevity Foundation and supported by college interns funded through the Massachusetts Life Science Center’s Internship Challenge program. Development of several of the protocols and all of the serum validation tests and data analysis on this phase of the program was completed at Merrimack College in North Andover, MA.

ABOUT BACH PHARMA

Bach Pharma, Inc., (BACH), a privately held research and development pharmaceutical company is a global leader in the discovery and commercialization of revolutionary therapeutics to treat life threatening diseases. BACH directs the development of therapies for degenerative neurological illnesses which can dramatically reduce the cost of global health care. Bach is a proud member of the MassBio Council and a host company for the Massachusetts Life Science Center Internship Challenge. Media Contacts: Mark Henry, CEO Telephone: 978-794-5510
Email: mhenry@bachpharma.com
www.bachpharma.com

XXX

BACH PHARMA, INC. APPOINTS WILLIAM S. LYNN, MD AS LIFETIME DIRECTOR EMERITUS

North Andover, Massachusetts, USA (February 10, 2013) – During the February 2, 2013 Meeting of the Board of Directors of Bach Pharma, Inc. held in Durham, North Carolina, Chairman of the Board Dr. Steven L. Stroup announced the appointment of Dr. William S. Lynn of Hillsboro, North Carolina to the first ever position of Director Emeritus for the Company. Dr. Lynn has held the positions of Director, Vice President and Director of Science for Bach Pharma for the past 12 years. He continues to oversee the planning, design and reporting of all of Bach’s research and intellectual property. Dr. Lynn is a recognized thought leader in clinical research, with special emphasis in the areas of oxidative stress, inflammation, metabolism, neurodegeneration and the central nervous system. Dr. Lynn has written over 130 publications and books, and coined the term of his book titled “Neuroimmunodegeneration” with co-writer Dr. Paul K.Y. Wong in 1998.

Dr. Lynn received his undergraduate training in Alabama at Auburn University, and his MD degree at Columbia University in New York. He completed his postdoctoral fellowships at the University of Pennsylvania and Duke University. A Markle Scholar at Duke University, Dr. Lynn went on to become Professor of Medicine and Associate Professor of Biochemistry, where he became a lifelong enthusiastic fan of Duke Basketball. In 1992, after holding professorial positions at The University of Texas, Galveston, Departments of Internal Medicine and Human Nutrition, Dr. Lynn continued on to his current position of Visiting Scientist at the University of Texas, MD Anderson Cancer Center in Smithville, Texas.

Dr. Lynn has been a Clinical Research Physician at Cato Research in Durham, North Carolina since 1992, where he is responsible for managing the design, protocols, direction and interpretation of clinical trials and research from Phase 1 through Phase 4 of products under development. He has also coordinated reporting information to the FDA on adverse events and safety monitoring.

In his remarks to Dr. Lynn on the presentation of this award, Bach Pharma CEO, Mark O. Henry, detailed Dr. Lynn’s remarkable history and praised his work and integrity. “There is no one who knows more about oxidative stress in the human body,” he said. “Dr. Lynn’s knowledge has undoubtedly placed Bach Pharma in a leadership role in developing treatment for all manners of illness caused by oxidative stress. We are truly thankful for his association with our company and present him this award which confers a lifetime position on our Board of Directors.”

About Bach Pharma
Bach Pharma, Inc., based in North Andover, MA is a pharmaceutical company engaged in the discovery, development, and commercialization of new therapeutics for the treatment of life threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia BiLateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum promotes and facilitates broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint research activities related to disease control, treatment and prevention, clinical and translational research, regulatory science, and the development of new health technologies.

Incorporated in 2001, Bach developed the proprietary manufacturing technologies for its proven phthalazinedione drug platform, and owns all of the intellectual property that encompasses this entire class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of phthalazinediones. Bach maintains one of the world’s most active monosodium luminol research programs focused on specific compound platforms and their derivates. Bach is an enthusiastic member of the MassBio Council, Advancing Massachusetts Biotechnology for worldwide medical benefits, and a proud host company of the Massachusetts Life Sciences Center Internship Challenge Program.

About Cato Research Ltd
Cato Research is a contract research organization (CRO) providing a complete range of services specializing in innovative development strategies for pharmaceutical and biotechnology companies through all stages of the clinical development process. Cato Research has strategic offices through-out the world, including Tel Aviv, Israel, Fourways, South Africa, and Quebec, Canada. Cato Research is a strategic alliance partner and CRO for Bach Pharma with offices located in the Bay Colony Corporate Center in Waltham, Massachusetts.

###

For more information about Cato Research companies please visit their main website www.cato.com, contact them by telephone 919.361.CATO (2286), or email info@cato.com. For additional information about Bach Pharma please visit their website at www.bachpharma.com, contact them by telephone 978.794.5510, or email info@bachpharma.com. For information about this press release please contact Dr. Norman Spencer at: normanspencer60@gmail.com.

BACH PHARMA, INC. APPOINTS MR. DAN CATO AS PRESIDENT

North Andover, Massachusetts, USA (February 1, 2013) – During the recent Meeting of the Board of Directors of Bach Pharma, Inc., Chairman of the Board Dr. Steven L. Stroup announced the appointment of Mr. Daniel Cato of Durham, North Carolina to the position of President of Bach Pharma, Inc. Mr. Cato has served as a Director of Bach Pharma for the past year in addition to serving the position of Vice President of International Regulatory Affairs.

Mr. Cato is a Director and the Vice President of Project Operations for Cato Research Ltd. headquartered in Durham, North Carolina. Mr. Cato is also the Managing Director for Cato Research Washington located in Rockville, Maryland, where he is in close contact with the FDA and other Federal US agencies. Dan is also on the Board of Directors of Cato Holding Company, Ltd, located in Durham, North Carolina. In addition, he is a Director and the Secretary/Treasurer of the RTP Federal Credit Union in North Carolina, with over 12,000 members and $104 million in assets.

Dan received his BS and MS in electrical engineering from North Carolina State University, and continued on to receive his MBA with an emphasis in health care from Duke University, Fuqua School of Business Global Executive Program, the world’s first global MBA program for senior executives. Dan brings with him over 20 years of experience in corporate management and pharmaceutical clinical trial management and research.

Bach Pharma CEO, Mr. Mark O. Henry, said, “Dan will undoubtedly continue to be a tremendous help to Bach Pharma. His experience in the area of regulatory affairs and clinical trials combined with his overall management experience will greatly add to Bach’s management team.”

About Bach Pharma
Bach Pharma, Inc., based in North Andover, MA is a pharmaceutical company engaged in the discovery, development, and commercialization of new therapeutics for the treatment of life threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia BiLateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum promotes and facilitates broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint research activities related to disease control, treatment and prevention, clinical and translational research, regulatory science, and the development of new health technologies.

Incorporated in 2001, Bach developed the proprietary manufacturing technologies for its proven phthalazinedione drug platform, and owns all of the intellectual property that encompasses this entire class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of phthalazinediones. Bach maintains one of the world’s most active monosodium luminol research programs focused on specific compound platforms and their derivates.

Bach is an enthusiastic member of the MassBio Council, Advancing Massachusetts Biotechnology for worldwide medical benefits, and a proud host company of the Massachusetts Life Sciences Center Internship Challenge Program.

About Cato Research Ltd
Cato Research is a contract research organization (CRO) providing a complete range of services specializing in innovative development strategies for pharmaceutical and biotechnology companies through all stages of the clinical development process. Cato Research has strategic offices through-out the world, including Tel Aviv, Israel, Fourways, South Africa, and Quebec, Canada. Cato Research is a strategic alliance partner and CRO for Bach Pharma with offices located in the Bay Colony Corporate Center in Waltham, Massachusetts.

THE FOUNDATION FOR THE NIH LAUNCHES FIRST U.S.–RUSSIA SCIENTIFIC FORUM PLANNING MEETING TO ADVANCE RESEARCH COLLABORATIONS

Moscow, Russia (April 20 2011) — The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, is facilitating the first planning meeting for the U.S.-Russia Scientific Forum in Moscow, Russia later this month.

The U.S.-Russia Scientific Forum was created as a result of the 2009 U.S.-Russia Bi-Lateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum will promote and facilitate broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint research activities related to disease control, treatment and prevention, clinical and translational research, and regulatory science, and the development of new health technologies.

“We are excited to develop a joint research agenda based on common interests that will stimulate US-Russian scientific collaborations and generate discoveries to improve the health of people everywhere,‖ said Dr. Roger I. Glass, Director of Fogarty International Center at NIH. ―By encouraging the free flow of information we hope to share best practices in biomedical research and speed the progress of discovery.”

The U.S.-Russia Forum was established through the FNIH, with a $1.27 million gift from Eli Lilly and Company as the founding private partner, and Fogarty International Center (FIC) and the NIH Clinical Center (CC) as the lead NIH participants. The Institute of Medicine of the National Academy of Sciences of the U.S. will also be an active participant of the program. The Forum planning meeting facilitated by the FNIH and hosted at the RAS will be held in Moscow on April 25-26, 2011.

“Through public-private, collaborative partnerships, FNIH supports a wide range of initiatives that advance scientific research, train scientists and clinical researchers, educate the public and generate support for medical discovery‖, said Dr. Scott Campbell, Executive Director and CEO of the Foundation for the NIH. ―The U.S.-Russia Scientific Forum is an example of how FNIH is working to engage global stakeholders to participate in transformative public-private research partnerships to improve human health.”

Active participation of the private sector will be critical in facilitating collaborations and engaging the best and brightest scientists in the U.S. and Russia. FNIH has engaged with a wide range of U.S. and Russian-based companies interested in broader U.S. – Russian collaboration in behavioral and biomedical research. Those participating in the first organizational meeting include Abbott, Amgen, American Chamber of Commerce in Russia, Amway, Bach Pharma, Becton Dickinson, Bristol-Myers Squibb, Boston Scientific, Coca-Cola, Eli Lilly and Company, GalenBio, Genzyme, Johnson & Johnson, MedBioPharm, PepsiCo, Pfizer and Worldwide Clinical Trials.

“We are looking forward to start new cooperation with NIH. Together with our American partners we initiated six general directions, that is, brain research, cardiovascular diseases, oncology, child care, infectious diseases and translational research,‖ said Professor Anatoly Ivanovich Grigoriev, Vice-President of the Russian Academy of Sciences. ―These areas embrace the key problems of human health worldwide; however, the Forum is open for a variety of ideas. Science and business people should combine their efforts. Our endeavor will be appreciated in our two countries and by the international community as well. We anticipate that the Forum will emerge as a medium that links together the best intellectual powers strongly committed to make life better.”

Dr. Scott Campbell, CEO of FNIH, Dr. Roger I. Glass, Director of the Fogarty International Center and NIH, and Professor Anatoly Grigoriev, Vice-President of the Russian Academy of Sciences will lead the two-day meeting that will include distinguished researchers from the United States and Russian Federation.

For more information about the U.S. – Russia Scientific Forum please visit www.fnih.org

About The Russia/US Cooperative Medical Sciences Program
The U.S.-Russia Forum in Health Sciences was formed under the framework of the U.S.-Russia Bilateral Presidential Commission (http://www.state.gov/p/eur/ci/rs/usrussiabilat/index.htm), and guided by several agreements between U.S. and Russian scientific and health agencies to collaborate on topics involving disease control and prevention, development of new therapies, and other emerging technologies in the field of health care (http://www.globalhealth.gov/news/news/070609.html; http://www.fic.nih.gov/programs/regional/russia_eurasia/russia.htm). The Forum’s activities will address those goals. About the Foundation for the NIH Established by the United States Congress to support the mission of the NIH—improving health through scientific discovery in the search for cures—the Foundation for the NIH is a leader in identifying and addressing complex scientific and health issues. The Foundation is a non-profit, 501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities. For additional information about the Foundation for the NIH, please visit www.fnih.org

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., USA, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

Press Contact:
Jenna Mills
Communications Manager
301.435-2613
jmills@fnih.org

BACH PHARMA ANNOUNCES PREVENTIVE DRUG DEVELOPMENT PROGRAM

US Company initiates a new program to complete health-prevention

Development Program January 4, 2010 — Bach Pharma, Inc, a privately held drug development company based in North Andover, Mass., today announced the launch of a Preventive Drug Development Program (PDDP) to discover and develop medical options that will help health care providers alter patient behavior to improve patient health.

In addition to developing new drugs, the initiative, undertaken in cooperation with sponsors, foundations, and corporate partners, will identify issues that affect the medical community’s nearterm ability to deliver cost-effective, preventive drugs to patients. The PDDP also will provide assessments of drug design, education, delivery and regulations.

“Health care providers around the world are increasingly concerned with rising cost of delivering health care cost-effectively,” said Bach Pharma’s Science Director, William S. Lynn M.D. “Our new initiative will help providers better understand the range of medically-based prevention options while educating patients on steps they can take to improve their health. As important, the drugs we are developing, aimed at preventing devastating disease symptoms, will help lower costs of our health care system.”

“The direction of patient-centered medicine is poised to undergo significant change, as cost pressures continue to rise across the health care delivery system,” he said. “It is possible that by the end of this decade, as care providers and patients gain a better understanding of medicine-based preventative measures, prevention will become the new norm when it comes to maintaining good health.”

“In the age of individualized medicine, we now have the ability to genetically identify these syndromes, even before birth. We have the tools and the knowledge to alleviate and combat many genetic diseases before they manifest themselves, such as ataxia-telangiectasia, Ushers syndrome, and retinopathy of prematurity.”

Steven L. Stroup M.D., Bach Pharma’s Chairman of the Board, remarked, “The medicines and information developed through the PDDP will provide widespread benefit in the United States and globally. We have scientific documentation of the strong, positive therapeutic effects of Bach Pharma’s disease-prevention drugs. With our understanding of the cascading effects of viruses, injuries, environmental and genetic diseases, we believe that during the next decade we’ll be able to integrate this knowledge to better health care outcomes”.

Bach Pharma’s product development pipeline includes candidates that can prevent symptoms induced by various stressors, including unfolded proteins, saturated fatty acids, infections, trauma and antioxidant deficiencies as observed in atherosclerosis, metabolic syndrome and many neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis and amyotrophic lateral sclerosis. Bach Pharma’s research has identified drugs shown to be effective in preventing symptoms in these disease states.